These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 1216856)

  • 21. Dietary factors in the management of Parkinson's disease.
    Kempster PA; Wahlqvist ML
    Nutr Rev; 1994 Feb; 52(2 Pt 1):51-8. PubMed ID: 8183469
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 3-O-methyldopa and the response to levodopa in Parkinson's disease.
    Nutt JG; Woodward WR; Gancher ST; Merrick D
    Ann Neurol; 1987 Jun; 21(6):584-8. PubMed ID: 3606046
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease.
    Greenamyre JT; Eller RV; Zhang Z; Ovadia A; Kurlan R; Gash DM
    Ann Neurol; 1994 Jun; 35(6):655-61. PubMed ID: 8210221
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modulation of the motor response to dopaminergic drugs in a parkinsonian model of combined dopaminergic and noradrenergic degeneration.
    Pérez V; Sosti V; Rubio A; Barbanoj M; Rodríguez-Alvarez J; Kulisevsky J
    Eur J Pharmacol; 2007 Dec; 576(1-3):83-90. PubMed ID: 17888901
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The history of dopamine and levodopa in the treatment of Parkinson's disease.
    Fahn S
    Mov Disord; 2008; 23 Suppl 3():S497-508. PubMed ID: 18781671
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacological basis of akinesia in Parkinson's disease.
    Narabayashi H
    J Neural Transm Suppl; 1983; 19():143-51. PubMed ID: 6583305
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Value of the probenecid test in the diagnosis and treatment of parkinson disease].
    Vanderheyden JE; Noel G; Mendlewicz J
    Acta Neurol Belg; 1982; 82(6):339-52. PubMed ID: 7164768
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Hyperuricemia in Parkinson's syndrome--by chance or probable?].
    Babucke G; Sagebiel L; Mertz DP
    MMW Munch Med Wochenschr; 1976 Nov; 118(46):1489-90. PubMed ID: 825768
    [No Abstract]   [Full Text] [Related]  

  • 29. The therapeutic potential of neurotrophic factors in the treatment of Parkinson's disease.
    Lindsay RM; Altar CA; Cedarbaum JM; Hyman C; Wiegand SJ
    Exp Neurol; 1993 Nov; 124(1):103-18. PubMed ID: 8282068
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The effect of liposomal form of L-Dopa on the level of dopamine, its metabolites, and phospholipid metabolism in the striatum of mice with experimental parkinsonian syndrome].
    Iurasov VV; Podgornyĭ GI; Kucherianu VG; Kudrin VS; Nikushkin EV; Zhigal'tsev IV; Sandalov IuG; Kaplun AP; Shvets VI; Kryzhanovskiĭ GN
    Biull Eksp Biol Med; 1996 Dec; 122(12):614-7. PubMed ID: 9280455
    [No Abstract]   [Full Text] [Related]  

  • 31. Relating mode of action to clinical practice: dopaminergic agents in Parkinson's disease.
    Riederer P; Gerlach M; Müller T; Reichmann H
    Parkinsonism Relat Disord; 2007 Dec; 13(8):466-79. PubMed ID: 17919963
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Reconsiderations in the treatment of Parkinson's disease with levodopa: some pharmacodynamic evidence].
    Zappia M; Nicoletti A; Muñoz-S D; Tapia-Núñez J
    Rev Neurol; 2009 Jul 1-15; 49(1):33-40. PubMed ID: 19557698
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Fracture of the distal end of the femur in Parkinson's disease].
    Ferraro C; Lunardo C; Nolli AL
    Clin Ortop; 1974; 25(3):165-73. PubMed ID: 4471321
    [No Abstract]   [Full Text] [Related]  

  • 34. Postencephalitic stereotyped involuntary movements responsive to L-Dopa.
    Picard F; de Saint-Martin A; Salmon E; Hirsch E; Marescaux C
    Mov Disord; 1996 Sep; 11(5):567-70. PubMed ID: 8866499
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The apomorphine test for diagnosis of parkinsonian syndrome].
    Piccini P; Del Dotto P; Napolitano A; Pardini C; Bonuccelli U
    Riv Neurol; 1990; 60(6):221-3. PubMed ID: 2100046
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Levodopa-induced alterations in speech rate in advanced Parkinson's disease.
    De Letter M; Santens P; De Bodt M; Boon P; Van Borsel J
    Acta Neurol Belg; 2006 Mar; 106(1):19-22. PubMed ID: 16776432
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.
    Jenner P; Marsden CD
    J Neural Transm Suppl; 1986; 20():11-39. PubMed ID: 3091760
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Drug therapy in Parkinson's disease].
    van Hilten JJ; Roos RA
    Ned Tijdschr Geneeskd; 1999 Jan; 143(5):234-40. PubMed ID: 10086151
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Updates in practical neurology--I. The principles of modern levodopa therapy in Parkinson's disease].
    Klivényi P; Vécsei L
    Ideggyogy Sz; 2007 Jan; 60(1-2):61-4. PubMed ID: 17432097
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Parkinson Study Group.
    Ann Neurol; 1996 Jan; 39(1):37-45. PubMed ID: 8572664
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.